Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096846 | 0.88 | MAPT (0.42) | APPALDH1A1 | |
| SCHEMBL10457449 | 0.87 | APP (0.59) | APPALDH1A1KCNH2CA12CA1 | |
| SCHEMBL14764547 | 0.81 | CA12 (0.50) | APPALDH1A1CA12CA1CA9 | |
| SCHEMBL4819508 | 0.81 | ALDH1A1 (0.60) | APPALDH1A1CA12CA1CA9 | |
| SCHEMBL304730 | 0.81 | TAAR1 (0.60) | ALDH1A1 | |
| SCHEMBL10458215 | 0.80 | APP (0.53) | APPALDH1A1 | |
| SCHEMBL6420718 | 0.80 | DRD4 (0.50) | DRD2DRD4DRD3 | |
| SCHEMBL1620167 | 0.78 | APP (0.52) | APPALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL7362924 | 0.76 | NPC1 (0.40) | ALDH1A1 | |
| SCHEMBL2628228 | 0.76 | L3MBTL1 (0.59) | APPALDH1A1KCNH2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3034074-A1 | Compound for treatment of myotonic dystrophy type 1 | Universitat De València, Estudi General (ES) | 2016-06-22 | — | — | EP | claimed |
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3233073-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | Universitat De València, Estudi General (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097299-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034074-A1 | Compound for treatment of myotonic dystrophy type 1 | Universitat De València, Estudi General (ES) | 2016-06-22 | — | — | EP | disclosed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8354092-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2468734-A1 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | Siemens Medical Solutions USA, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2129666-A2 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | Siemens Medical Solutions USA, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2008124703-A2 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | APP 3382/4885ALDH1A1 387/4885KCNH2 2971/4885 |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | APP 1338/4885ALDH1A1 3602/4885KCNH2 3093/4885 |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | CA9, CA4, CA13 | APP 3382/4885ALDH1A1 387/4885KCNH2 2971/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | APP 1366/4885ALDH1A1 3509/4885KCNH2 3349/4885 |
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | MBNL1, SMN1; SMN2, SQSTM1 | APP 1731/4885ALDH1A1 3387/4885KCNH2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.